Japan OKs Bayer's Nexavar for thyroid cancer

Nexavar

Building on approvals in the U.S. and EU, Bayer Healthcare said Japan has approved Nexavar to treat patients with unresectable differentiated thyroid carcinoma. Nexavar was approved in the U.S. last November for advanced thyroid cancer and by the EU in May. The drug, which Bayer shares with developer Onyx Pharmaceuticals--now part of Amgen ($AMGN)--generated €771 million ($1.06 billion) for Bayer alone in 2013. It counts certain types of kidney cancer among its FDA-approved indications. Announcement | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.